Medical Need and Market Opportunity
Patients with HCV who receive orthotopic liver transplants are at risk for recurrent HCV infections in the transplanted organs. Many of these patients will experience accelerated development of fibrosis and progression to cirrhosis of the transplanted liver due to the recurrence of HCV. Even after successful treatment with drugs designed to clear the HCV infection, fibrotic changes in the liver may persist for many years. The HCV landscape is expected to continue to evolve dramatically over the next five to ten years with the introduction of interferon-free regimens with greater efficacy and tolerability over the current antiviral therapies.